DCC2811 |
Jcp405 |
Covalent dual inhibitor of DPAP1 and DPAP3 |
|
DCC2812 |
Jcp410 |
Covalent dual inhibitor of DPAP1 and DPAP3 |
|
DCC2813 |
Jcp474 |
Novel potent inhibitor of Mpro |
|
DCC2814 |
Jcp678 |
Novel irriversable serine hydrolases inhibitor |
|
DCC2815 |
jd-5006 |
Peripheral Selective CB1 Receptor Antagonist |
|
DCC2816 |
Jesridonin |
Novel apoptosis inducer, significantly inhibiting tumor growth in the xenograft model |
|
DCC2817 |
Jfd00950 |
Novel human flap endonuclease 1 (FEN1) inhibitor with in vitro inhibition of flap cleavage activity as well as cytotoxic activity against a colon cancer cell line, DLD-1 |
|
DCC2818 |
Jg2-38 |
Novel inhibitor of the heat shock protein 70 (Hsp70) with anti-proliferative activity in breast and prostate cancer cells |
|
DCC2819 |
Jh-i-17 |
Novel type I Interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitor, binding preferentially to unphosphorylated IRAK4 |
|
DCC2820 |
Jh-i-25 |
Novel Interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitor, binding preferentially to unphosphorylated IRAK4 |
|
DCC2821 |
Jk-136 |
Novel Ras homologous A (RHOA) inhibitor, potently inhibiting cell viability and migration/invasion of gastric cancer (GC) cell lines, and mouse xenografts, diversely expressing RHOA, binding affinity for RHOA was >140-fold greater than Rhosin, a nonclinic |
|
DCC2822 |
Jk-31 (vegfr2/cdk1 Inhibitor) |
Novel specific dual inhibitor of vascular endothelial growth factor receptor 2 (VEGFR2) and cyclin-dependent kinase 1 (CDK1), targeting cell cycle progression and angiogenesis |
|
DCC2823 |
Jlj-334 |
Potent non-nucleoside inhibitor of HIV-1 reverse transcriptase (NNRTIs) |
|
DCC2824 |
Jmv2951 |
Novel potent GHS-R1a agonist (EC50 (Ca ): 1.6 nM), significantly stimulating GH secretion |
|
DCC2825 |
Jmv3168 |
Novel ghrelin receptor (GHS-R1a) antagonist [IC 50 (affinity): 5 nM IC 50 (Ca ): 60 nM] |
|
DCC2826 |
Jmv4484 |
Novel partial inverse agonist of GHS-R1a (K i = 3 nM, EC 50 = 70 nM, Emax = −37%) |
|
DCC2827 |
Jmx0207 |
Novel inhibitor of viral protease function, suppressing Zika virus Infection both In vitro and In vivo |
|
DCC2828 |
Jmx0254 |
Novel Potent NS4B Inhibitor for the Treatment of Dengue Virus Infection |
|
DCC2829 |
Jmx0510-2 |
Novel Potent Human Adenovirus Inhibitor, showing improved anti-HAdV activity (IC50 = 0.27 μM), significantly decreasing cytotoxicity (CC50 = 156.8 μM), and lowering in vivo toxicity (maximum tolerated dose = 150 mg/kg in hamster) as compared with niclosam |
|
DCC2830 |
Jnj-1013 |
Novel potent and selective IRAK1 degrader, effectively degraded cellular IRAK1 protein with a DC50 of 3 nM in HBL-1 cells |
|
DCC2831 |
Jnj-10311795 |
Novel, potent dual inhibitor of the leukocyte proteases cathepsin G and chymase |
|
DCC2832 |
Jnj-17029259 |
Vascular endothelial growth factor receptor-2 (VEGF-2) kinase inhibitor |
|
DCC2833 |
Jnj-17148066 |
Estrogen receptor ESR1 agonist |
|
DCC2834 |
Jnj-1930942 |
Novel Positive Allosteric Modulator of the α7 Nicotinic Acetylcholine Receptor |
|
DCC2835 |
Jnj-20788560 |
Selective delta opioid receptor agonist as a potent and efficacious antihyperalgesic agent |
|
DCC2836 |
Jnj-26076713 |
Novel EthR inhibitor, boosting antituberculous activity of ethionamide |
|
DCC2837 |
Jnj-28330835 |
Selective androgen receptor modulator with minimal prostate hypertrophic activity stimulating sexual behavior in female rats |
|
DCC2838 |
Jnj-28583867 |
Histamine H3 receptor antagonist and serotonin reuptake inhibitor |
|
DCC2839 |
Jnj-40068782 |
Novel potent, selective, and systemically active positive allosteric modulator (PAM) of mGlu2-receptors |
|
DCC2840 |
Jnj-40255293 |
Novel Adenosine A 2A /A 1 Antagonist With Efficacy In Preclinical Models of Parkinson's Disease |
|